Skip to main content

Table 4 Summary of rescue medication use-total grams used by visit (per-protocol set)

From: Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz

Time interval

Statistic

Artz

Durolane

(5 × 2.5 ml)

(1 × 3 ml, 4 × sham)

( n  = 158)

( n  = 161)

Pre treatment

n (%)

2 (1.3%)

4 (2.5%)

 

Mean (SD)

1.25 (0.35)

1.25 (0.87)

 

Median

1.25

1.00

Week 4 to week 6

n (%)

20 (12.7%)

26 (16.1%)

 

Mean (SD)

4.48 (5.81)

4.75 (5.41)

 

Median

2.00

2.75

Week 6 to week 10

n (%)

13 (8.2%)

14 (8.7%)

 

Mean (SD)

3.12 (3.90)

4.14 (6.13)

 

Median

1.50

1.50

Week 10 to week 14

n (%)

10 (6.3%)

6 (3.7%)

 

Mean (SD)

2.75 (3.83)

3.58 (3.76)

 

Median

1.00

2.25

Week 14 to week 18

n (%)

9 (5.7%)

5 (3.1%)

 

Mean (SD)

4.56 (6.05)

2.60 (2.30)

 

Median

1.50

2.50

Week 18 to week 26

n (%)

21 (13.3%)

17 (10.6%)

 

Mean (SD)

6.10 (6.28)

6.26 (6.94)

 

Median

3.50

3.50

  1. Only patients that used rescue medication were included. Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). SD, standard deviation.